ECOR

electroCore Stock Price

1.48
0.00 (0.0%)
1.48
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
$30.66
Canadian Level 1 + USA
Monthly Subscription
for only
$38.05
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
electroCore Inc ECOR NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 1.48 04:00:00
Open Price Low Price High Price Close Price Previous Close
1.48
Bid Price Ask Price Spread News
1.49 1.51 0.02 - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 1.48 USD

electroCore Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 67.27M 45.45M 42.47M $ 2.39M $ - -1.53 -1.90
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

electroCore News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ECOR Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.541.551.451.50347,189-0.06-3.9%
1 Month1.531.751.451.57412,182-0.05-3.27%
3 Months1.422.041.361.68464,4150.064.23%
6 Months0.904.250.771.804,053,1560.5864.44%
1 Year1.514.250.32011.622,653,402-0.03-1.99%
3 Years18.0020.250.32011.941,193,548-16.52-91.78%
5 Years18.0020.250.32011.941,193,548-16.52-91.78%

electroCore Description

electroCore, Inc. is a medical device company, engaged in the commercialization and development of a platform non-invasive Vagus Nerve Stimulation ("nVNS") therapy that can be self-administered by patients. electroCore was founded in 2005 and has primarily focused on headache conditions (migraine and cluster headache). In July 2020, the U.S. Food and Drug Administration ("FDA") granted the Company an Emergency Use Authorization (EUA) authorizing the use of the Company's gammaCore Sapphire(TM) CV nVNS therapy at home or in a healthcare setting to acutely treat adult patients with known or suspected COVID-19 who are experiencing exacerbation of asthma-related dyspnea and reduced airflow, and for whom approved drug therapies are not tolerated or provide insufficient symptom relief.


Your Recent History
NASDAQ
ECOR
electroCor..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.